About: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
Creator	Faraz, Syed Mckay, Matthew Quadeer, Ahmed
Source	Medline; PMC
abstract	The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.
has issue date	2020-02-25(xsd:dateTime)
bibo:doi	10.3390/v12030254
bibo:pmid	32106567
has license	cc-by
sha1sum (hex)	7a4d9e01bf11dea3e6a2bdae9109b508a6677a24
schema:url	https://doi.org/10.3390/v12030254
resource representing a document's title	Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
has PubMed Central identifier	PMC7150947
has PubMed identifier	32106567
schema:publication	Viruses
resource representing a document's body	covid:7a4d9e01bf11dea3e6a2bdae9109b508a6677a24#body_text
is schema:about of	named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'PROTECTION' named entity 'T CELL' named entity 'PERFORMED' named entity 'ASSOCIATED' named entity 'DEVELOPMENT' named entity 'EPITOPES' named entity 'TO CONTROL' named entity 'OFFER' named entity 'CHINA' named entity 'MHC' named entity 'PROPOSED' named entity 'NEW' named entity 'ALLELES' named entity 'GENETIC SIMILARITY' covid:arg/7a4d9e01bf11dea3e6a2bdae9109b508a6677a24 named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'virus' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'China' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'Vaccine Targets' named entity 'SARS-CoV' named entity 'coronaviruses' named entity 'alleles' named entity 'epitopes' named entity 'virus' named entity 'SARS-CoV-2' named entity 'mutation' named entity 'epitope' named entity 'ViPR' named entity 'antibody' named entity 'MHC' named entity 'alleles' named entity 'SARS-CoV' named entity 'epitope' named entity 'epitopes' named entity 'epitopes' named entity 'SARS-CoV' named entity 'immune responses' named entity 'global population' named entity 'receptor' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'epitopes' named entity 'epitopes' named entity 'global health emergency' named entity 'immunogenic' named entity 'cell assays' named entity 'antibodies' named entity 'epitopes' named entity 'infection' named entity 'vaccine' named entity 'SARS-CoV' named entity 'neutralizing antibodies' named entity 'preliminary results' named entity 'nucleocapsid' named entity 'epitopes' named entity 'SARS-CoV' named entity 'phylogenetic analysis' named entity 'SARS-CoV' named entity 'epitopes' named entity 'immunogen' named entity 'SARS-CoV-2' named entity 'MERS-CoV' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'SARS-CoV-2' named entity 'nucleocapsid' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'coding sequence' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software